Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been given an average recommendation of “Moderate Buy” by the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $22.4545.

Several equities analysts have recently commented on ATEC shares. Morgan Stanley set a $23.00 price objective on shares of Alphatec in a report on Tuesday, December 2nd. Wells Fargo & Company boosted their target price on Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, October 16th. Needham & Company LLC increased their price objective on shares of Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, October 31st. JPMorgan Chase & Co. initiated coverage on Alphatec in a research report on Friday, October 24th. They set an “overweight” rating and a $19.00 target price on the stock. Finally, Loop Capital set a $25.00 price objective on shares of Alphatec in a report on Wednesday, December 10th.

Insider Buying and Selling at Alphatec

In other news, major shareholder Squadron Capital Llc sold 250,000 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $20.80, for a total value of $5,200,000.00. Following the completion of the sale, the insider directly owned 11,145,045 shares of the company’s stock, valued at approximately $231,816,936. This represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David R. Pelizzon sold 250,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $20.62, for a total value of $5,155,000.00. Following the transaction, the director directly owned 10,895,045 shares in the company, valued at approximately $224,655,827.90. This represents a 2.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 3,403,342 shares of company stock worth $69,111,381. 20.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alphatec

Hedge funds have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd acquired a new stake in shares of Alphatec in the 3rd quarter valued at approximately $34,000. Osterweis Capital Management Inc. purchased a new position in Alphatec in the second quarter worth $37,000. Nisa Investment Advisors LLC lifted its holdings in Alphatec by 22.4% in the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after acquiring an additional 1,045 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alphatec during the 3rd quarter worth $73,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Alphatec during the 3rd quarter worth $74,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Stock Up 1.5%

Shares of NASDAQ ATEC opened at $19.87 on Friday. The company has a market capitalization of $2.95 billion, a P/E ratio of -19.11 and a beta of 1.08. The company has a debt-to-equity ratio of 43.02, a current ratio of 1.99 and a quick ratio of 1.24. The company has a 50 day simple moving average of $18.90 and a 200-day simple moving average of $15.29. Alphatec has a 1 year low of $8.70 and a 1 year high of $22.66.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million during the quarter, compared to analysts’ expectations of $182.78 million. Alphatec’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.28) EPS. On average, equities research analysts predict that Alphatec will post -1.08 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.